Treatment with a platelet-activating factor receptor antagonist improves hemodynamics and reduces epinephrine requirements, in a lethal rodent model of anaphylactic shock.
Fiche publication
Date publication
mars 2020
Journal
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GENY Bernard
Tous les auteurs :
Tacquard C, Oulehri W, Collange O, Garvey LH, Nicoll S, Tuzin N, Geny B, Mertes PM
Lien Pubmed
Résumé
In some cases, anaphylactic shock (AS) is still lethal, despite rapid use of epinephrine. High doses of epinephrine are associated with severe complications. Platelet-activating factor (PAF) is secreted in massive amounts during AS, and a high plasma level is correlated with increased AS severity.
Mots clés
anaphylaxis, epinephrine, ovalbumin, platelet-activating factor, shock
Référence
Clin Exp Allergy. 2020 03;50(3):383-390